Daily versus weekly azithromycin in cystic fibrosis patients

McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., Serisier D., Harris M., Bowler S.

Source: Eur Respir J 2007; 30: 487-495
Journal Issue: September
Disease area: Paediatric lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., Serisier D., Harris M., Bowler S.. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007; 30: 487-495

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Source: Eur Respir J 2002; 20: 658-664
Year: 2002



Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002



Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012



Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients
Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
Year: 2017



Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005

Fosfomycin for pseudomonas related exacerbations of cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008


Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008


Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of S. aureus and haemophilus
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006


Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006



Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015


Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 379s
Year: 2002

Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015


Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011


Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013



Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003



Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016


Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF)
Source: Eur Respir J 2002; 20: Suppl. 38, 526s
Year: 2002

Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003